Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Abstract EN

Central nervous system (CNS) metastases occur frequently in oncogene-driven non-small cell lung cancer (NSCLC).

Standard treatment approaches can potentially delay systemic treatment (surgical intervention) or result in neurocognitive impairment (radiotherapy).

Recently, next-generation tyrosine kinase inhibitors (TKIs) have demonstrated remarkable intracranial activity.

However, most clinical trials did not enroll patients suffering neurological symptoms.

Our study aimed to assess the CNS activity of targeted therapies in this patient population.

We present a case series of nine NSCLC patients with either EGFR mutation or ALK rearrangement and symptomatic CNS metastases that were treated with TKIs.

Clinicopathological characteristics, treatment, and outcomes were analyzed.

Most patients presented with symptomatic CNS metastases at time of metastatic disease presentation (6/9).

Additionally, the majority of patients had leptomeningeal disease (6/9) and multiple parenchymal metastases.

Patients presented with a variety of CNS symptoms with the most common being nausea, vomiting, headache, and confusion.

Most patients (6/9) responded rapidly both clinically and radiographically to the targeted treatment, with a marked correlation between systemic and intracranial radiographic response.

In conclusion, upfront use of next-generation TKIs in patients with oncogene-driven NSCLC with symptomatic CNS metastases is associated with reasonable intracranial activity and represents a valuable treatment option.